Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Completed · Phase 4

Conditions studied: Metastatic Renal Cell Carcinoma, Metastatic Melanoma

In brief

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Key facts

Study ID

NCT00414765

Run by

Novartis Pharmaceuticals

People needed

26

Starts

2008-09-03

Expected to finish

2010-03-28

Last updated by the study team

2021-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Performance Status Eastern Cooperative Oncology Group: 0 or 1.
• Adequate organ function.

You may not qualify if…

• Pregnancy or lactation.
• Prior treatment with any form of IL-2.
• Organ transplant. Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• USC/Kenneth Norris Comprehensive Cancer Center — Los Angeles, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• James Graham Brown Cancer Center — Louisville, Kentucky, United States
• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.